How does FDA Section 524B work?

What Section 524B is trying to achieve

Section 524B is not just a filing requirement, it is a product-security gate for medical devices. Its purpose is to force cybersecurity evidence into the premarket process so security is designed, documented, and reviewable before a device reaches patients, while still expecting manufacturers to keep managing risk after release as the product environment changes.

That changes the burden from “show the device works” to “show the device can be maintained safely over time.” The practical implication is that security documentation has to describe the device, its dependencies, its update path, and the controls that keep it supportable in the field, not just the initial build.

What the submission has to demonstrate

The section expects a manufacturer to provide cybersecurity information that is specific enough for a reviewer to understand how the device is protected, how weaknesses will be found, and how fixes will be delivered. That usually means the submission should connect threat modelling, vulnerability handling, patching, and coordinated disclosure into one coherent product-security story rather than treating them as separate artefacts.

Medical Device Security Guide is the most direct internal reference for this topic because it covers fda section 524b, premarket cybersecurity, SBOMs, and postmarket controls in one place.

Practically, a strong submission also shows that the organisation knows what software and components are in scope, which vulnerabilities are likely to matter, and how the manufacturer will coordinate disclosures without losing control of the remediation process.

Why postmarket operations matter as much as premarket review

Section 524B becomes operational after approval because device risk does not freeze at launch. Inventory, patching, and dependency tracking have to continue so the manufacturer can identify affected products, assess exposure, and push updates when a vulnerability lands in the device itself or in a component it depends on.

That makes postmarket governance part of compliance, not a nice-to-have support function. A device can be well documented at submission time and still become noncompliant in practice if the vendor cannot reliably see where it is deployed, what software is inside it, or how to update it when a flaw is disclosed.

Update processes are especially important because medical devices often sit in regulated, operationally fragile environments. If patching is slow, the manufacturer needs a defensible way to prioritise fixes, communicate risk, and maintain secure operation until remediation is complete.

Risk and Threat Considerations

Medical devices create concentrated exposure because one weakness can affect patient safety, clinical availability, and hospital operations at the same time. The largest failure mode is not just a vulnerable product, but a product that cannot be inventoried, updated, or remediated quickly enough once a weakness is known.

Failure mechanism: Attackers or researchers disclose a flaw in the device or a dependency, but the manufacturer lacks accurate asset visibility, reliable update distribution, or a coordinated disclosure path, so vulnerable units remain in service longer than intended.

Impact: The result can be prolonged exposure, delayed remediation, and broader operational disruption, especially where devices are deployed at scale or embedded in clinical workflows that cannot tolerate downtime.

Practitioner Guidance

What to verify: Confirm that the submission and the operating model describe the same device population, component inventory, and update pathway. If the postmarket process cannot identify where the device is deployed or which software build is running, the security programme is incomplete even if the premarket package looks strong.

Decision rule: If a vulnerability could affect deployed units, treat inventory accuracy and patch orchestration as first-order security controls, not administrative tasks. If the device cannot be updated quickly, document the compensating control, the exposure window, and the escalation path in advance.

Practitioner takeaway: Section 524B works best when teams treat cybersecurity evidence as a lifecycle obligation, because premarket assurance only holds if the manufacturer can keep tracking, updating, and supporting the device after release.

Related resources from NHI Mgmt Group

• FDA Section 524B
• How does Data Safety Section (Google Play) work?
• How does FISA Section 702 work?
• How does FDA premarket cybersecurity work?